NCT05031715 is a NA clinical trial of Berberine Phytosome in Glucose Metabolism Disorders, sponsored by Azienda di Servizi alla Persona di Pavia.

Who is sponsoring NCT05031715?

NCT05031715 is sponsored by Azienda di Servizi alla Persona di Pavia.

What drugs are being tested in NCT05031715?

Interventions in NCT05031715: Berberine Phytosome.

What condition does NCT05031715 study?

NCT05031715 studies Glucose Metabolism Disorders.

Is NCT05031715 still recruiting?

NCT05031715 is currently status unknown. Last updated 3 March 2022.

Last reviewed 2022-03-03 · How we verify

NCT05031715

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Berberine and Altered Fasting Glucose

Status unknown NA Last updated 3 March 2022

What this trial tests

NA trial testing Berberine Phytosome in Glucose Metabolism Disorders in 50 participants. Status unknown.

Timeline

2 March 2020

Primary endpoint
28 May 2020

25 July 2022

Quick facts

Lead sponsor	Azienda di Servizi alla Persona di Pavia
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	2 March 2020
Primary completion	28 May 2020
Estimated completion	25 July 2022
Sites	1 location across Italy

Drugs / interventions tested

Berberine Phytosome

Conditions studied

Glucose Metabolism Disorders — all drugs for Glucose Metabolism Disorders →

Sponsor

Azienda di Servizi alla Persona di Pavia — full company profile →

Who can join

18 and older, any sex, with Glucose Metabolism Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study was to evaluate the effectiveness of a food supplement, berberine phytosome, which contributes to the control of blood sugar and the improvement of insulin resistance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus.
He Q, Dong H, Guo Y, Gong M, et al · · 2022 · cited 13× · PMID 36465656 · DOI 10.3389/fendo.2022.1074348

Verify or expand the search:

Other recruiting trials for Glucose Metabolism Disorders

Currently open trials in the same condition.

NCT06763562 — Food Orders on Blood Glucose and Fuel Use At Rest · NA · recruiting
NCT06674980 — Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DF · NA · recruiting
NCT06051318 — Relationship Between Individual Effect of Diet on Postprandial Glycemia and Gut Microbiome Profile in Healthy Subjects · NA · recruiting
NCT06358716 — Glycaemic Index Determination in Oral Nutrition Supplements · NA · recruiting
NCT06878781 — Postprandial Metabolome and Metabolic Flexibility · NA · recruiting

Other Azienda di Servizi alla Persona di Pavia trials

Trials by the same sponsor.

NCT07377409 — Beneficial Effects of Supplementation With CRONILIEF™ (Palmitoylethanolamide Phospholipids) in Diabetic Subjects With Ne · NA · not yet recruiting
NCT06954038 — Evaluate the Beneficial Effects of an Oral Nutritional Supplement Based on Leonurus Cardiaca for the Improvement of Mood · NA · not yet recruiting
NCT06955234 — Berbevis Dose-finding Study in Subjects With Impaired Fasting Glucose · NA · not yet recruiting
NCT06942897 — Evaluation of a Dietary Supplement Containing Melissa Officinalis Formulated in Phospholipids on Mood Well-being and Cor · NA · not yet recruiting
NCT05730985 — From the Gut to the Strut: Reducing Inflammation for Healthy Muscles · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05031715 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Azienda di Servizi alla Persona di Pavia
Last refreshed: 3 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05031715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing